

Mometasone furoate (Asmanex Twisthaler[®]) (No. 79/03)
Schering-Plough

Summary of Recommendation

10 November, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Accepted for restricted use within NHS Scotland

Mometasone is the fourth inhaled steroid licensed for treatment of asthma. It is available as a dry powder inhaler. It has a similar efficacy and adverse event profile to other currently available inhaled steroids. It is suitable for use as a second line agent following treatment failure on first line inhaled steroids.

Professor David H Lawson
Chairman